Changes in lipid profile after roxadustat treatment in cirrhosis of liver patients ; A randomized control trial

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230710002

Enrollment

105

Registered

2023-07-10

Start date

2023-07-07

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis of liver patients who is anemic Anemia, Cirrhosis of Liver, Treatment with Roxadustat a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, lipid profile

Interventions

70 patients with cirrhosis of liver disease with anemia will be randomised to this group, those will recieve roxadustat 50 mg, thrice weekly for 6 weeks. Roxadustat is an orally administered, hypoxia

Experimental Drug,Sham Comparator Other

Roxadustat 50 mg,Standard medical treatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with cirrhosis of liver (Child pugh A or B) 2. Anemia. 3. Age: More than 18 years

Exclusion criteria

Exclusion criteria: : 1. Patients with Child Pugh C liver cirrhosis 2. Hepatocellular carcinoma 3. Pregnancy or lactation 4. Active variceal bleeding 5. Adult polycystic kidney disease 6. Hypo/Hyperthyroidism 7.Hyperkalemia 8. Patient with co-morbid condition (COPD, CKD, CCF, MI etc.)

Design outcomes

Primary

Measure	Time frame
Total cholesterol level 6 weeks Lipoprotein level,LDL level 6 weeks Lipoprotein level,Triglyceride level 6 weeks Lipoprotein level,HDL level 6 weeks Lipoprotein level	—

Secondary

Measure	Time frame
Hemoglobin level 6 weeks Hematology analyzer	—

Countries

Bangladesh

Contacts

Public ContactMd. Rahim

Bangabandhu Sheikh Mujib Medical University

dt.rahim62@gmail.com01712144358

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026